The balance sheet gives him room to move - Lal PathLabs is sitting on about Rs.1,400 crore of net cash and no debt, and can blend cash with equity, if a compelling platform emerges, Goel said.

Earnings call Dr. Lal PathLabs reported Q1 FY26 revenue of ₹670 crore, up 11.3% YoY, with PAT growing 24.3% to ₹134 crore. EBITDA margin held strong at 28.7%. Management reaffirmed 11–12% full-year ...

Dr. Lal Path Labs posts earnings dip on Indian labour code changes; test demand strong Dr. Lal Path Labs reported a lower third-quarter profit on Friday after taking a one-time charge linked to ...

BENGALURU, May 11 (Reuters) - India's Dr. Lal PathLabs Ltd (DLPA.NS), opens new tab on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from COVID-related ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

About Dr. Lal PathLabs Ltd. Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. It also involves in providing diagnostic and healthcare ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.